Peginterferon beta - Allozyne

Drug Profile

Peginterferon beta - Allozyne

Alternative Names: AZ 01; PEG-IFN-beta - Allozyne

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allozyne
  • Class Interferons; Proteins
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 15 Apr 2016 No recent reports on development identified - Phase-I for Multiple sclerosis (In volunteers) in USA (Parenteral)
  • 18 Oct 2011 Interim adverse events, pharmacokinetics and pharmacodynamics data from a phase Ib trial in volunteers released by Allozyne
  • 11 Jan 2011 Topline adverse events and pharmacodynamics data from a phase I trial in Multiple sclerosis released by Allozyne
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top